Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin Receives NASDAQ Notification Related To Late Filing Of 2008 Annual Report On Form 20-F
Amarin Receives NASDAQ Notification Related To Late Filing Of 2008 Annual Report On Form 20-F DUBLIN, Ireland, July 7, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that on July 6, 2009, the Company received a written notification from the Nasdaq Stock Market stating that it is not
View HTML
Toggle Summary Amarin Reports Preliminary Unaudited Financial Results For The Six And Twelve Months Ended December 31, 2008
Amends Terms to Extend Bridge Financing Reports Delay in Filing 2008 Annual Report
View HTML
Toggle Summary Amarin Reports Preliminary Unaudited Financial Results For The Six And Twelve Months Ended December 31, 2008
Amends Terms to Extend Bridge Financing Reports Delay in Filing 2008 Annual Report
View HTML
Toggle Summary Amarin Announces Revision To Non-Binding Term Sheet For Private Placement Of Up To $55 Million
Amarin Announces Revision To Non-Binding Term Sheet For Private Placement Of Up To $55 Million DUBLIN, Ireland, July 22, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that it has revised the terms of the previously announced non-binding term sheet relating to the private placement of
View HTML
Toggle Summary Amarin Announces Results From Exploratory Phase 2a Study Of EN101 In Myasthenia Gravis
Amends Ester Neurosciences Acquisition Agreement
View HTML
Toggle Summary Amarin Announces $2.6 Million Bridge Financing
Amarin Announces $2.6 Million Bridge Financing DUBLIN, Ireland, May 26, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has signed a term sheet for a private placement of convertible bridge loan notes (“Bridge Financing”) in the amount of $2.6 million with certain existing
View HTML
Toggle Summary Amarin Receives Special Protocol Assessment Agreement From The FDA For Phase 3 Cardiovascular Trial
Amarin Receives Special Protocol Assessment Agreement From The FDA For Phase 3 Cardiovascular Trial DUBLIN, Ireland, May 6, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment
View HTML
Toggle Summary Amarin's Marketing Authorization Application for AMR101 to Treat Huntington's Disease Accepted for review by EMEA
DUBLIN, Ireland, April 8, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that the European Medicines Agency (EMEA) has accepted for review the Company's Marketing Authorization Application (MAA) for AMR101 (ultra-pure ethyl- EPA) in patients with Huntington’s disease.
View HTML
Toggle Summary Amarin To Present At The Cowen & Company 29th Annual Health Care Conference
DUBLIN, Ireland, March 11, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Mr. Thomas Lynch, Chairman and Chief Executive Officer, will present at the Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18, 2009 at 8.00 am Eastern Time.
View HTML
Toggle Summary Amarin To Present At The 11th Annual BIO CEO & Investor Conference
DUBLIN, Ireland, February 3, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Mr. Thomas Lynch, Chairman and Chief Executive Officer, will present at the upcoming 11 th Annual BIO CEO & Investor Conference on Monday, February 9, 2009 at 2.45 pm Eastern Time. The event will be held
View HTML
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation